U.S. markets close in 1 hour
  • S&P 500

    4,158.68
    -15.17 (-0.36%)
     
  • Dow 30

    34,315.66
    -66.47 (-0.19%)
     
  • Nasdaq

    13,326.43
    -103.55 (-0.77%)
     
  • Russell 2000

    2,213.22
    -11.41 (-0.51%)
     
  • Crude Oil

    66.25
    +0.88 (+1.35%)
     
  • Gold

    1,867.20
    +29.10 (+1.58%)
     
  • Silver

    28.31
    +0.94 (+3.44%)
     
  • EUR/USD

    1.2162
    +0.0016 (+0.13%)
     
  • 10-Yr Bond

    1.6420
    +0.0070 (+0.43%)
     
  • GBP/USD

    1.4145
    +0.0043 (+0.31%)
     
  • USD/JPY

    109.1680
    -0.1790 (-0.16%)
     
  • BTC-USD

    43,507.76
    -2,014.82 (-4.43%)
     
  • CMC Crypto 200

    1,206.71
    +8.79 (+0.73%)
     
  • FTSE 100

    7,032.85
    -10.76 (-0.15%)
     
  • Nikkei 225

    27,824.83
    -259.67 (-0.92%)
     

Optinose to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 5, 2020

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Conference Call and Webcast Scheduled for Thursday, March 5 at 7:30 a.m. Eastern Time

YARDLEY, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the fourth quarter and year-end 2019, before market open on Thursday, March 5, 2020.

Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. The call is scheduled to start at 7:30 a.m. Eastern Time on Thursday, March 5, 2020.

To participate on the conference call, please dial (866) 916-4761 from the U.S. or +1 (409) 216-6496 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until Thursday, March 12, 2020 by dialing (855) 859-2056 from the U.S. or +1 (404) 537-3406 from outside the U.S. and entering conference ID #9566036. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com. In addition, a replay of the webcast will be available on the Company website for 60 days following the event.

About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531